AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

12th BioVaria to take place on 8 – 9 May 2019 in Munich

April 4, 2019

MUNICH--(BUSINESS WIRE)--Apr 4, 2019--On 8–9 May 2019, decision makers from biotech, pharma and finance will come together in Munich for the 12 th BioVaria to learn about commercially attractive academic inventions and initiate partnerships with research teams, entrepreneurs and technology transfer professionals from all over Europe.

66 peer-selected, patent-protected technologies originating from as many research institutes, universities and university hospitals will be featured.

Further program highlights include a panel discussion on “From stem cells to therapy: Development of cell based approaches in regenerative medicine” and BioVaria’s dedicated Startup Pitch & Partner program. The expanded format of the Startup Pitch & Partner program provides attractive opportunities for entrepreneurs and venture capitalists, with interactive pitches, one-on-one mentoring sessions and speed dating between startups and investors. Based on last year’s success it attracted more applications from European startups than ever before. A preview of all technologies selected for BioVaria 2019 and the startups selected for this year’s Startup Pitch & Partner program is available online.

BioVaria is organised by Ascenion and 14 additional technology transfer organisations from 5 European nations.

Preview BioVaria’s Technologies and Startups online

  • Explore the technologies presented in 10-min oral presentations and posters
  • Get a first impression of the participating startups

Register now at www.biovaria.org

Who should attend?

  • Scouts and business developers from the international biopharmaceutical industry looking for cutting-edge inventions to complement their companies’ R&D portfolios
  • Life-science investors looking for attractive startups or IP assets as investment opportunities
  • Technology transfer professionals and scientists from public research institutions who have patent-protected technologies available for licensing or partnering

Patron:

Bavarian Ministry of Economic Affairs, Regional Development and Energy

Sponsors:

Bio M, Abbvie, Else Kröner-Fresenius-Stiftung, ISAR Bioscience, Johnson & Johnson Innovation, HERTIN & Partner, Kador & Partner, NLC, Vossius & Partner

Startup Sponsors:

24IP Law Group, Accelero Bioanalytics, Charles River, German Accelerator Life Sciences, IASON Consulting, K&L Gates, LSI Life Science Inkubator, LSP, ttopstart, TVM Capital Life Science

Technology transfer partners:

Ascenion, Austria Wirtschaftsservice Gesellschaft, BayPAT, DKFZ - German Cancer Research Center, DZIF - German Center for Infection Research, EMBLEM Technology Transfer, IOCB Tech, Lead Discovery Center, LMU Munich, Max Planck Innovation, Netval, PROvendis, TechnologieAllianz, University of Pardubice, VIS

Network partners:

ASTP-Proton, BIO Deutschland, BioRN

Media partners:

Business Wire, Going Public, LABIOTECH.eu, transkript

View source version on businesswire.com:https://www.businesswire.com/news/home/20190404005356/en/

CONTACT: Ascenion GmbH

Esther Lange

T: +49-(0)89-318814-22

lange@ascenion.de

KEYWORD: AUSTRIA EUROPE GERMANY SWITZERLAND

INDUSTRY KEYWORD: TECHNOLOGY DATA MANAGEMENT HEALTH BIOTECHNOLOGY PHARMACEUTICAL PROFESSIONAL SERVICES OTHER PROFESSIONAL SERVICES

SOURCE: Ascenion GmbH

Copyright Business Wire 2019.

PUB: 04/04/2019 07:22 AM/DISC: 04/04/2019 07:22 AM

http://www.businesswire.com/news/home/20190404005356/en